Including a first-in-human trial
Extensive R&D studies have demonstrated our vectors ability to induce long-lasting, intense and broad cellular immune responses against differents pathogens.
Numerous protective animal studies with back-to-back comparison with other vaccines/vaccine-candidates show our vaccine vectors induce protective immunity much better than plasmid or RNA-based vaccines.
Theravectys lentiviral vector platform covers a wide number of indications in infectious diseases and oncology. For more information you may see our pipeline.
Theravectys has been granted a Global Exclusive Licence on lentiviral vectors for all vaccine applications by the Pasteur Institute.